213 related articles for article (PubMed ID: 11514832)
21. Furanocoumarin compounds isolated from
Pengnam S; Jitkaroon W; Srisuphan R; Wongprayoon P; Rayanil KO; Charoensuksai P
Acta Pharm; 2024 Mar; 74(1):67-79. PubMed ID: 38554381
[TBL] [Abstract][Full Text] [Related]
22. Balancing the efficacy and toxicity of chemotherapy in colorectal cancer.
Braun MS; Seymour MT
Ther Adv Med Oncol; 2011 Jan; 3(1):43-52. PubMed ID: 21789155
[TBL] [Abstract][Full Text] [Related]
23. Marginal effects of glucose, insulin and insulin-like growth factor on chemotherapy response in endothelial and colorectal cancer cells.
Volkova E; Robinson BA; Willis J; Currie MJ; Dachs GU
Oncol Lett; 2014 Feb; 7(2):311-320. PubMed ID: 24396438
[TBL] [Abstract][Full Text] [Related]
24. Temporal Dynamics of Genomic Alterations in a
Wong HL; Zhao EY; Jones MR; Reisle CR; Eirew P; Pleasance E; Grande BM; Karasinska JM; Kalloger SE; Lim HJ; Shen Y; Yip S; Morin RD; Laskin J; Marra MA; Jones SJM; Schrader KA; Schaeffer DF; Renouf DJ
JCO Precis Oncol; 2018; 2():. PubMed ID: 32913994
[No Abstract] [Full Text] [Related]
25. Current Landscape in Organic Nanosized Materials Advances for Improved Management of Colorectal Cancer Patients.
Ginghină O; Hudiță A; Zaharia C; Tsatsakis A; Mezhuev Y; Costache M; Gălățeanu B
Materials (Basel); 2021 May; 14(9):. PubMed ID: 34066710
[TBL] [Abstract][Full Text] [Related]
26. Discovery of the Next-Generation Platinum-Based Anticancer Agents for Combating Oxaliplatin-Induced Drug Resistance.
Sun Z; Han J; Xu J; Song W; Cui Y; Liu Y; Yang L; Meng X; Huang J; Gao Q; Liu S
J Med Chem; 2024 Jun; ():. PubMed ID: 38845105
[TBL] [Abstract][Full Text] [Related]
27. A Colorectal Cancer 3D Bioprinting Workflow as a Platform for Disease Modeling and Chemotherapeutic Screening.
Sbirkov Y; Molander D; Milet C; Bodurov I; Atanasov B; Penkov R; Belev N; Forraz N; McGuckin C; Sarafian V
Front Bioeng Biotechnol; 2021; 9():755563. PubMed ID: 34869264
[TBL] [Abstract][Full Text] [Related]
28. Chemotherapy treatments for metastatic colorectal cancer: is evidence-based medicine in practice?
Field KM; Kosmider S; Jefford M; Jennens R; Green M; Gibbs P
J Oncol Pract; 2008 Nov; 4(6):271-6. PubMed ID: 20856756
[TBL] [Abstract][Full Text] [Related]
29. Looking ahead: what will change in colorectal cancer treatment?
Saltz LB
Gastrointest Cancer Res; 2009 Mar; 3(2 Suppl):S16-8. PubMed ID: 19461916
[TBL] [Abstract][Full Text] [Related]
30. Oxaliplatin-induced lung fibrosis.
Shah A; Udwadia ZF; Almel S
Indian J Med Paediatr Oncol; 2009 Jul; 30(3):116-8. PubMed ID: 20838550
[TBL] [Abstract][Full Text] [Related]
31. Colorectal Cancer Chemotherapy: The Evolution of Treatment and New Approaches.
McQuade RM; Stojanovska V; Bornstein JC; Nurgali K
Curr Med Chem; 2017; 24(15):1537-1557. PubMed ID: 28079003
[TBL] [Abstract][Full Text] [Related]
32. Immunogenic death of colon cancer cells treated with oxaliplatin.
Tesniere A; Schlemmer F; Boige V; Kepp O; Martins I; Ghiringhelli F; Aymeric L; Michaud M; Apetoh L; Barault L; Mendiboure J; Pignon JP; Jooste V; van Endert P; Ducreux M; Zitvogel L; Piard F; Kroemer G
Oncogene; 2010 Jan; 29(4):482-91. PubMed ID: 19881547
[TBL] [Abstract][Full Text] [Related]
33. Use of Patient-Derived Organoids as a Treatment Selection Model for Colorectal Cancer: A Narrative Review.
Furbo S; Urbano PCM; Raskov HH; Troelsen JT; Kanstrup Fiehn AM; Gögenur I
Cancers (Basel); 2022 Feb; 14(4):. PubMed ID: 35205817
[TBL] [Abstract][Full Text] [Related]
34. Liver Immune Microenvironment and Metastasis from Colorectal Cancer-Pathogenesis and Therapeutic Perspectives.
Zeng X; Ward SE; Zhou J; Cheng ASL
Cancers (Basel); 2021 May; 13(10):. PubMed ID: 34067719
[TBL] [Abstract][Full Text] [Related]
35. Alternative Treatment Options in Patients with Colorectal Cancer Who Encounter Fluoropyrimidine-Induced Cardiotoxicity.
Saif MW
Onco Targets Ther; 2020; 13():10197-10206. PubMed ID: 33116601
[TBL] [Abstract][Full Text] [Related]
36. The anticancer effect of (1S,2S,3E,7E,11E)-3,7,11, 15-cembratetraen-17,2-olide(LS-1) through the activation of TGF-β signaling in SNU-C5/5-FU, fluorouracil-resistant human colon cancer cells.
Kim EJ; Kang JI; Kwak JW; Jeon CH; Tung NH; Kim YH; Choi CH; Hyun JW; Koh YS; Yoo ES; Kang HK
Mar Drugs; 2015 Mar; 13(3):1340-59. PubMed ID: 25786063
[TBL] [Abstract][Full Text] [Related]
37. Decreased camptothecin sensitivity of the stem-cell-like fraction of Caco2 cells correlates with an altered phosphorylation pattern of topoisomerase I.
Roy A; Tesauro C; Frøhlich R; Hede MS; Nielsen MJ; Kjeldsen E; Bonven B; Stougaard M; Gromova I; Knudsen BR
PLoS One; 2014; 9(6):e99628. PubMed ID: 24960044
[TBL] [Abstract][Full Text] [Related]
38. Mechanism of trifluorothymidine potentiation of oxaliplatin-induced cytotoxicity to colorectal cancer cells.
Temmink OH; Hoebe EK; van der Born K; Ackland SP; Fukushima M; Peters GJ
Br J Cancer; 2007 Jan; 96(2):231-40. PubMed ID: 17242697
[TBL] [Abstract][Full Text] [Related]
39. Irinotecan and oxaliplatin: an overview of the novel chemotherapeutic options for the treatment of advanced colorectal cancer.
Grivicich I; Mans DR; Peters GJ; Schwartsmann G
Braz J Med Biol Res; 2001 Sep; 34(9):1087-103. PubMed ID: 11514832
[TBL] [Abstract][Full Text] [Related]
40. Recent experience with oxaliplatin or irinotecan combined with 5-fluorouracil and leucovorin in the treatment of colorectal cancer.
Kuebler JP; de Gramont A
Semin Oncol; 2003 Aug; 30(4 Suppl 15):40-6. PubMed ID: 14523794
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
